107 results
Page 2 of 6
6-K
EX-99.2
ebng7op 5uei
11 May 23
Current report (foreign)
8:00am
6-K
EX-99.3
9svtvb2lqqoz289 53f
11 May 23
Current report (foreign)
8:00am
6-K
EX-1.1
pnu3d 8dgr472q4fen0f
13 Apr 23
Current report (foreign)
4:01pm
424B5
tsyrlpvzwm5es
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
7j5zt6p dujs7x0r5hd
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.1
wgdgzgzmdrh
4 Apr 23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4:50pm
6-K
EX-10.1
9q3g5ys2cb28q
21 Dec 22
Current report (foreign)
7:45am
6-K
EX-99.1
tyghlkf
9 Nov 22
Current report (foreign)
7:53am
6-K
EX-99.2
oh6 xm6e0p81bbwzsn
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.2
6f9lgktr97sr465kf6
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
hdvks93w
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.2
4fnznc5ya9x
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.3
y44g02rfugepmsg6m
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
fpxhy999mhrwttozi
7 Apr 22
Current report (foreign)
4:01pm
6-K
EX-99.1
dzz aay2zo
24 Mar 22
InflaRx Reports Full Year 2021 Financial and Operating Results
8:40am
6-K
EX-99.1
abm17 pzln
16 Feb 22
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
7:30am
6-K
e7f82efc7
16 Feb 22
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
7:30am
6-K
EX-99.1
zhtgssge rm
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am
6-K
EX-99.2
ffwv708a4f1 d3
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am